MX2019000761A - Anticuerpos anti-virus del zika y metodos de uso. - Google Patents
Anticuerpos anti-virus del zika y metodos de uso.Info
- Publication number
- MX2019000761A MX2019000761A MX2019000761A MX2019000761A MX2019000761A MX 2019000761 A MX2019000761 A MX 2019000761A MX 2019000761 A MX2019000761 A MX 2019000761A MX 2019000761 A MX2019000761 A MX 2019000761A MX 2019000761 A MX2019000761 A MX 2019000761A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- zikv
- methods
- zika virus
- bind
- Prior art date
Links
- 208000020329 Zika virus infectious disease Diseases 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 title 1
- 241000907316 Zika virus Species 0.000 abstract 3
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 208000001455 Zika Virus Infection Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000007501 viral attachment Effects 0.000 abstract 1
- 230000008478 viral entry into host cell Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona anticuerpos monoclonales o fragmentos de unión al antígeno de estos, que se unen a glicoproteínas del ZIKV, composiciones farmacéuticas que comprenden los anticuerpos y métodos de uso. Los anticuerpos de la invención son útiles para inhibir o neutralizar la actividad del ZIKV, con lo cual se brinda un medio para tratar o prevenir la infección por ZIKV en humanos. En algunas modalidades, la invención proporciona el uso de uno o más anticuerpos que se unen al ZIKV para prevenir la unión viral y/o el ingreso en células hospedadoras. Los anticuerpos de la invención se pueden utilizar de forma profiláctica o terapéutica y se pueden utilizar solos o en combinación con uno o más agentes antivirales o vacunas adicionales.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662363546P | 2016-07-18 | 2016-07-18 | |
| US201762474753P | 2017-03-22 | 2017-03-22 | |
| PCT/US2017/042447 WO2018017497A1 (en) | 2016-07-18 | 2017-07-17 | Anti-zika virus antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000761A true MX2019000761A (es) | 2019-07-04 |
Family
ID=59416830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000761A MX2019000761A (es) | 2016-07-18 | 2017-07-17 | Anticuerpos anti-virus del zika y metodos de uso. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10421804B2 (es) |
| EP (1) | EP3484917A1 (es) |
| JP (1) | JP6993401B2 (es) |
| KR (1) | KR20190030206A (es) |
| CN (1) | CN109641952A (es) |
| AU (1) | AU2017300277A1 (es) |
| BR (1) | BR112019000798A2 (es) |
| CA (1) | CA3030618A1 (es) |
| CL (1) | CL2019000124A1 (es) |
| CO (1) | CO2019000968A2 (es) |
| IL (1) | IL263818A (es) |
| MA (1) | MA45671A (es) |
| MX (1) | MX2019000761A (es) |
| PH (1) | PH12018502673A1 (es) |
| SG (1) | SG11201811363YA (es) |
| TW (1) | TW201815821A (es) |
| UY (1) | UY37336A (es) |
| WO (1) | WO2018017497A1 (es) |
| ZA (1) | ZA201808603B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018010789A1 (en) | 2016-07-13 | 2018-01-18 | Humabs Biomed Sa | Novel antibodies specifically binding to zika virus epitopes and uses thereof |
| TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| BR112020002050A2 (pt) * | 2017-08-03 | 2020-09-08 | Antheia, Inc. | epimerases engenheiradas alcaloides benzilisoquinolina e métodos de produção de alcaloides benzilisoquinolina |
| WO2019042555A1 (en) | 2017-08-31 | 2019-03-07 | Humabs Biomed Sa | MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF |
| CN116327926A (zh) * | 2018-03-15 | 2023-06-27 | 中外制药株式会社 | 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法 |
| WO2019204654A1 (en) | 2018-04-18 | 2019-10-24 | Utah State University | Compositions and methods for zika virus characterization and vaccine development |
| SG11202010531SA (en) | 2018-04-24 | 2020-11-27 | The Henry M Jackson Foundation For The Advancement Of Military Medicine Inc | Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following zikv infection or vaccination |
| MX2021002190A (es) | 2018-08-31 | 2021-05-14 | Regeneron Pharma | Estrategia de dosificacion que mitiga el sindrome de liberacion de citoquinas para los anticuerpos biespecificos cd3/cd20. |
| WO2020061159A1 (en) * | 2018-09-20 | 2020-03-26 | Vanderbilt University | Human antibodies to zika virus |
| US20220332800A1 (en) | 2018-11-20 | 2022-10-20 | Takeda Vaccines, Inc. | Novel anti-zika virus antibodies and uses thereof |
| KR20210148154A (ko) * | 2019-04-03 | 2021-12-07 | 리제너론 파마슈티칼스 인코포레이티드 | 세이프 하버 좌위 내로의 항체 코딩 서열의 삽입을 위한 방법 및 조성물 |
| CN111138534B (zh) * | 2019-12-31 | 2021-09-28 | 武汉班科生物技术股份有限公司 | 寨卡病毒囊膜蛋白的鼠源单克隆抗体 |
| CN111100201B (zh) * | 2019-12-31 | 2021-09-28 | 武汉班科生物技术股份有限公司 | 针对寨卡病毒囊膜蛋白的鼠源单克隆抗体 |
| JP2023527169A (ja) | 2020-05-20 | 2023-06-27 | タケダ ワクチン，インコーポレイテッド | 抗原の効力を決定するための方法 |
| WO2021236225A1 (en) | 2020-05-20 | 2021-11-25 | Takeda Vaccines, Inc. | Method for detection of zika virus specific antibodies |
| EP4153222A1 (en) | 2020-05-20 | 2023-03-29 | Takeda Vaccines, Inc. | Method for detection of zika virus specific antibodies |
| CN115697392A (zh) * | 2020-06-28 | 2023-02-03 | 神州细胞工程有限公司 | 一种降低病毒ade效应的方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| US7582298B2 (en) | 2006-06-02 | 2009-09-01 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human IL-6 receptor |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| TW200838550A (en) * | 2007-02-09 | 2008-10-01 | Novartis Ag | Organic compounds |
| RU2522002C2 (ru) | 2009-06-26 | 2014-07-10 | Ридженерон Фармасьютикалз, Инк. | Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом |
| MA37949B1 (fr) | 2012-09-12 | 2017-07-31 | Genzyme Corp | Polypeptides contenant fc ayant une glycosylation modifiée et une fonction effectrice réduite |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| JO3701B1 (ar) * | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
| TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
-
2017
- 2017-07-14 TW TW106123586A patent/TW201815821A/zh unknown
- 2017-07-17 US US15/651,387 patent/US10421804B2/en active Active
- 2017-07-17 SG SG11201811363YA patent/SG11201811363YA/en unknown
- 2017-07-17 KR KR1020197000620A patent/KR20190030206A/ko unknown
- 2017-07-17 CA CA3030618A patent/CA3030618A1/en not_active Abandoned
- 2017-07-17 WO PCT/US2017/042447 patent/WO2018017497A1/en unknown
- 2017-07-17 CN CN201780041806.7A patent/CN109641952A/zh active Pending
- 2017-07-17 BR BR112019000798A patent/BR112019000798A2/pt not_active IP Right Cessation
- 2017-07-17 MA MA045671A patent/MA45671A/fr unknown
- 2017-07-17 EP EP17745595.3A patent/EP3484917A1/en active Pending
- 2017-07-17 MX MX2019000761A patent/MX2019000761A/es unknown
- 2017-07-17 AU AU2017300277A patent/AU2017300277A1/en not_active Abandoned
- 2017-07-17 JP JP2019502258A patent/JP6993401B2/ja active Active
- 2017-07-19 UY UY0001037336A patent/UY37336A/es not_active Application Discontinuation
-
2018
- 2018-12-18 PH PH12018502673A patent/PH12018502673A1/en unknown
- 2018-12-19 IL IL263818A patent/IL263818A/en unknown
- 2018-12-20 ZA ZA2018/08603A patent/ZA201808603B/en unknown
-
2019
- 2019-01-16 CL CL2019000124A patent/CL2019000124A1/es unknown
- 2019-01-31 CO CONC2019/0000968A patent/CO2019000968A2/es unknown
- 2019-08-09 US US16/536,531 patent/US11117955B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CL2019000124A1 (es) | 2019-04-05 |
| CA3030618A1 (en) | 2018-01-25 |
| ZA201808603B (en) | 2019-08-28 |
| IL263818A (en) | 2019-01-31 |
| MA45671A (fr) | 2021-04-07 |
| AU2017300277A1 (en) | 2019-02-07 |
| JP2019528050A (ja) | 2019-10-10 |
| PH12018502673A1 (en) | 2019-11-11 |
| TW201815821A (zh) | 2018-05-01 |
| WO2018017497A1 (en) | 2018-01-25 |
| US11117955B2 (en) | 2021-09-14 |
| UY37336A (es) | 2018-02-28 |
| KR20190030206A (ko) | 2019-03-21 |
| SG11201811363YA (en) | 2019-01-30 |
| BR112019000798A2 (pt) | 2019-07-02 |
| US10421804B2 (en) | 2019-09-24 |
| CN109641952A (zh) | 2019-04-16 |
| EP3484917A1 (en) | 2019-05-22 |
| US20200062831A1 (en) | 2020-02-27 |
| JP6993401B2 (ja) | 2022-02-04 |
| CO2019000968A2 (es) | 2019-04-30 |
| US20180016324A1 (en) | 2018-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502673A1 (en) | Anti-zika virus antibodies and methods of use | |
| MX2021015687A (es) | Anticuerpos humanos contra glicoproteina del virus ebola. | |
| MX2021007679A (es) | Anticuerpos humanos para hemaglutinina de influenza. | |
| MX2023013140A (es) | Vacunas contra el virus de la hepatitis b. | |
| MX2022005253A (es) | Anticuerpos neutralizantes de poliomavirus. | |
| WO2020106358A8 (en) | Novel anti-zika virus antibodies and uses thereof | |
| MX2018003713A (es) | Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente). | |
| UY37449A (es) | Anticuerpos anti-chikv y usos de éstos | |
| PH12020551051A1 (en) | Human antibodies to influenza hemagglutinin | |
| MX2016009597A (es) | Terapias para el influenzavirus a subtipo h7n9. | |
| PH12017501943A1 (en) | Influenza virus neutralizing peptidomimetic compounds | |
| EA201990300A1 (ru) | Антитела к вирусу зика и способы их применения | |
| EA202191973A3 (ru) | Человеческие антитела к гликопротеину вируса эбола | |
| WO2017211843A8 (en) | ANTIVIRAL POLYCLONAL ANTIBODIES AGAINST EBOLA VIRUS AND USES THEREOF | |
| ECSP21039816A (es) | Anticuerpos monoclonales antirrábicos y cóctel de estos | |
| AR104480A1 (es) | Anticuerpos humanos contra la glicoproteína del virus del ébola |